Queenie Hui

• Established KOL network with 17 experts for endometrial cancer, a new area focus in AZ
• Identified the local treatment journey and testing practice of endometrial cancer in Hong Kong
• Provided medical insight through regular field visit and translated into future medical strategies
• Executed medical strategical planning for combination IO+PARPi therapy (durvalumab+olaparib) targeted for dMMR and pMMR endometrial cancer at pre-launched phase
• Organized 1 advisory board in Jun 2024 with 10 experts from O&G and clinical oncology in both private and public hospital to identify clinical gaps in DUO-E trial and help position IO+PARPi regimen at first line endometrial cancer
• Held a lunch symposium collaborated with OGSHK to increase the gynecological oncologists' awareness of the underlying science of IO+PARPi and the unmet needs of pMMR of endometrial cancer
• Successful built an KOL advocate to acknowledge the benefit of durvalumab and wrote a letter to DoH requesting for expedited review. Accelerated approval was granted within 1.5 months
• Closely collaborated with commercial team to deliver on-label congress update and disease area training monthly
• Conduct medical reviews for promotional material to ensure the scientific accuracy and compliance with local regulation

• Reviewed average of 250 promotional materials per month in Hong Kong, Taiwan and Macau in all cross therapeutic areas such as Vaccines, Inflammation and Immunology and Oncology etc in a timely manner
• Supervised promotional materials and external medical material reviews in accordance with internal policy, HKAPI and UMAO
• Collaborated with key stakeholders such as Local Medical Affairs Team and Marketing Team in Hong Kong and Taiwan
• Delivered updated trainings of promotional material and medical policies to relevant stakeholders

HKU Practicum under Hong Kong Medical Affairs Team

• Assembled 2 RSV advisory boards targeted on older adult and maternal immunization to gather insights from key external experts
• Initiated strategic digital medical content plans in Vaccine and I&I product such as PCV20 and Tofacitinib at post-launched phase under the supervision of Medical Director
• Developed medical to medical slide deck for Ritlecitinib at pre-launch phase for internal stakeholders

Medical Affairs Team-Oncology

• Supported and monitored Named Patient Programme of Enhertu at pre-launch phase
• Reviewed weekly Named Patient Programme status report update for ASCA
• Conducted reference check for Enhertu promotional materials to ensure the medical information are in alignment with references and laws & regulations

Marketing Team-Oncology

• Coordinated with PR agency for the launch of media activities for Enhertu in a timely manner
  

• Mounted and labeled plant specimens in accordance with protocol
• Captured digital photographs of re-mounted specimens of herbs and retouched the photographs by Adobe Photoshop
• Recorded and entered information of plant specimens
• Sorted and packed specimens for herbarium repository
• Reviewed and cross checked the information of entries based on Flora of china and Chinese Medicine Bibliography
• Compiled statistic reports on digitalization